Ohio State University’s Wexner Medical Center will be a multicenter clinical trial that will test an experimental COVID-19 vaccine in humans.
The vaccine was developed jointly through the University of Oxford and AstraZeneca, a biopharmaceutical company. The results of a giant early clinical trial in the UK have shown that the experimental vaccine is and triggers a strong immune response, generating antibodies and T cells, which trip and attack viral cells.
The trial will recruit approximately 30,000 adult volunteers at 80 sites in the United States to assess the extent to which the vaccine, called AZD1222, may affect other people from COVID-19.
Researchers from the state of Ohio plan to recruit about 500 adults for the randomized, double-blind, placebo-controlled trial.Study participants will get the experimental vaccine or placebo, blood samples will be taken and followed up with medical experts for two years.
“Wexner Medical Center is at the forefront of combat opposing COVID-19,” said Ohio State President Kristina M.Mr. Johnson.” We have been and will continue to be part of the solution.”
The effects of this and other clinical trials conducted through the COVID-19 Prevention Network (CoVPN) are to bring a COVID-19 vaccine to market, said Dr. Rama Mallampalli, president of the Department of Internal Medicine at the Ohio State School of Medicine..
“We are very pleased that the state of Ohio is taking this COVID-19 vaccine clinical trial to central Ohio,” Mallampalli said.”Our hospitals and researchers are qualified to conduct these trials for the purpose of saving lives in our network and beyond.”
The National Institute of Allergy and Infectious Diseases (NIAID) created CoVPN, an infectious disease experience from 4 of its networked paintings of existing clinical trials.This has allowed CoVPN to function quickly, establishing COVID-19 clinical trials at sites with a long history of studies and collaborations.
The Ohio State AIDS Clinical Trials Unit is a member of two of these NIAID-funded networks.
According to the National Institutes of Health, the vaccine uses an unrepeatable chimpanzee adenovirus to administer a SARS-CoV-2 protein to induce an immune response.SARS-CoV-2 is the virus that causes COVID-19.
“It’s time to expand a vaccine and/or drugs that can prevent sarS-CoV-2 transmission and the serious physical effects and deaths caused by COVID-19,” dr.Susan Koletar, director of the Division of Infectious Diseases.at Wexner Medical Center and lead researcher of the study.
“This requires unprecedented collaboration. Our well-established, top-established infectious diseases work hard with pneumologists, epidemiologists, other medical experts and networked paints to locate tactics to treat well and save this widespread disease.This is just one of many critical COVID-19 clinical trials underway in the state of Ohio, allowing us to treat patients at all stages of the disease.
The exam looks for volunteers who are at increased risk of exposure, such as teachers, lifeguards, students, factory staff, eating place staff, and people 65 years of age or older.More data on active clinical studies on COVID-19 will be had in https://www.coronaviruspreventionnetwork.org/understanding-clinical-studies/#active-studies